The record
| Class | musculoskeletal |
|---|---|
| Also known as | Ramatercept, ACVR2B-Fc, Activin Receptor Type IIB-Fc |
| Chain length | - |
| Molecular weight | 90,000 Da |
| Half-life | 10-15 days |
| Route | SC/IM |
| Studied for | Duchenne muscular dystrophy (clinical trials halted); Neuromuscular diseases (investigational); Muscle wasting conditions |
| Research use | Myostatin signaling research; Muscle hypertrophy studies; TGF-beta superfamily pathway analysis |
| What has been shown | Increases lean muscle mass; Increases thigh muscle volume; Improves bone mineral density; Reduces fat mass |
| How it works | Soluble decoy receptor that binds myostatin (GDF-8) and other TGF-beta superfamily ligands (activin A, GDF-11) with high affinity, preventing them from binding to endogenous ActRIIB receptors. Blocks myostatin's inhibitory signal on muscle growth, allowing unrestricted muscle development and hypertrophy. |
| Patent status | proprietary (Acceleron Pharma) |
| Regulatory status | development terminated (February 2011) |
Blank = not established in the record. Nothing is estimated to fill a gap.
Where it is matched
- Muscle Hypertrophy / Anabolic Signaling (affection, 64%)
- GH Pulsatility Environment (affection, 32%)
- Adult GH deficiency (illness, 30%)
- Anti-aging therapy (illness, 30%)
- Cardiac repair after myocardial infarction (illness, 40%)
- Duchenne muscular dystrophy (illness, 100%)
- Muscle wasting conditions (illness, 100%)
- Neuromuscular diseases (illness, 100%)
- Pediatric growth hormone deficiency (illness, 30%)
- Post-injury muscle recovery (illness, 40%)
- Post-stroke recovery (illness, 40%)
- Soft tissue repair (illness, 40%)
- Muscle loss or weakness (symptom, 67%)